COMPARATIVE EFFECTIVENESS OF APIXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH AND WITHOUT ACTIVE CANCER

In the AMPLIFY trial, apixabanwas non-inferior to low-molecular-weight heparinfollowed by warfarin in treatment of acute venous thromboembolism (VTE) and had significantly less major bleeding (MB). This observational studycompared risks of MB and recurrent VTE among patients with and without